Roche Gearing For CERA Renal Anemia BLA In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche readies CERA long-acting anti-anemia therapy BLA for 2006 filing. Four Phase III trials meet primary endpoint of hemoglobin maintenance.
You may also be interested in...
Roche Delays CERA Oncology Filing Until 2009
Roche is pushing back the timeline for filing its anti-anemia drug CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the company reported Feb. 1
Roche Delays CERA Oncology Filing Until 2009
Roche is pushing back the timeline for filing its anti-anemia drug CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the company reported Feb. 1
Roche Has “Reasonable” Chance Of Launching Its Long-Acting EPO In U.S.
Roche believes is has a "reasonable" chance of being able to launch its long-acting EPO product CERA in the U.S. upon approval despite expected patent challenges, the company said Sept. 13 at the Bear Stearns health care conference in New York.